You just read:

Multimedia Assets Now Available: Ipsen Biopharmaceuticals, Inc. announces FDA approval of Dysport® (abobotulinumtoxinA) for the treatment of lower limb spasticity in pediatric patients aged two and older

News provided by

Ipsen Biopharmaceuticals, Inc.

Aug 03, 2016, 15:37 ET